nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

06.03.2018 | Original Article

The roles of ¹¹C-acetate PET/CT in predicting tumor differentiation and survival in patients with cerebral glioma

verfasst von: Soyoung Kim, Dongwoo Kim, Se Hoon Kim, Mi-ae Park, Jong Hee Chang, Mijin Yun

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This prospective study aimed to evaluate the clinical values of ¹¹C–acetate positron emission tomography/computed tomography (PET/CT) in predicting histologic grades and survival in patients with cerebral glioma.

Methods

Seventy-three patients with surgically confirmed cerebral gliomas (19 grade II, 21 grade III, and 33 grade IV) who underwent ¹¹C–acetate PET/CT before surgery were included. Tumor-to-choroid plexus ratio (TCR), which was defined as the maximum standardized uptake value (SUV) of tumors to the mean SUV of choroid plexus, was compared between three World Health Organization (WHO) grade groups. Moreover, metabolic tumor volumes (MTV) were calculated. Progression-free survival (PFS) and overall survival (OS) curves were plotted using the Kaplan–Meier method, and differences in survival between groups were assessed using the log-rank test.

Results

Median TCR was 1.20 (interquartile range [IQR], 1.14 to 1.4) in grade II, 1.65 (IQR, 1.26 to 1.79) in grade III, and 2.53 (IQR, 1.93 to 3.30) in grade IV gliomas. Significant differences in TCR were seen among the three WHO grade groups (P < 0.001). In Cox regression analysis including TCR, MTV, molecular markers, and other clinical factors, TCR was prognostic for PFS (P = 0.016) and TCR and MTV were prognostic for OS (P = 0.024 [TCR], P = 0.030 [MTV]). PFS and OS were significantly shorter in patients with a TCR ≥ 1.6 than in those with a TCR < 1.6. OS were significantly shorter in patients with a MTV ≥ 1 than in those with a TCR < 1.

Conclusions

TCR on ¹¹C–acetate PET/CT significantly differed between low- and high-grade cerebral gliomas, and it showed the capability to further differentiate grade III from grade IV tumors. TCR and MTV were independent prognostic factors and predicted survival better than did the WHO grade.

Nur mit Berechtigung zugänglich

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-Oncology. 2015;17(Suppl 4):iv1–iv62.CrossRefPubMedPubMedCentral

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.CrossRefPubMed

Singhal T, Narayanan TK, Jacobs MP, Bal C, Mantil JC. ¹¹C-methionine PET for grading and prognostication in gliomas: a comparison study with ¹⁸F-FDG PET and contrast enhancement on MRI. J Nucl Med. 2012;53(11):1709–15.CrossRefPubMed

Lopci E, Riva M, Olivari L, Raneri F, Soffietti R, Piccardo A, et al. Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. Eur J Nucl Med Mol Imaging. 2017;44(7):1155–64.CrossRefPubMed

Bangiyev L, Rossi Espagnet MC, Young R, Shepherd T, Knopp E, Friedman K, et al. Adult brain tumor imaging: state of the art. Semin Roentgenol. 2014;49(1):39–52.CrossRefPubMed

Langen KJ, Galldiks N, Hattingen E, Shah NJ. Advances in neuro-oncology imaging. Nat Rev Neurol. 2017;13(5):279–89.CrossRefPubMed

Wong TZ, van der Westhuizen GJ, Coleman RE. Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am. 2002;12(4):615–26.CrossRefPubMed

Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neuro-Oncol. 2003;64(3):227–37.CrossRef

Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, Garlip G, et al. ¹⁸F-fluoro-l-thymidine and ¹¹C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46(12):1948–58.PubMed

10.

Miyake K, Shinomiya A, Okada M, Hatakeyama T, Kawai N, Tamiya T. Usefulness of FDG, MET and FLT-PET studies for the management of human gliomas. J Biomed Biotechnol. 2012;2012:205818.CrossRefPubMedPubMedCentral

11.

Singhal T, Narayanan TK, Jain V, Mukherjee J, Mantil J. ¹¹C-l-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol. 2008;10(1):1–18.CrossRefPubMed

12.

Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, et al. ¹¹C-acetate PET imaging of prostate cancer. J Nucl Med. 2002;43(2):181–6.PubMed

13.

Ho CL, Yu SC, Yeung DW. ¹¹C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003;44(2):213–21.PubMed

14.

Liu RS, Chang CP, Chu LS, Chu YK, Hsieh HJ, Chang CW, et al. PET imaging of brain astrocytoma with 1-¹¹C-acetate. Eur J Nucl Med Mol Imaging. 2006;33(4):420–7.CrossRefPubMed

15.

Tsuchida T, Takeuchi H, Okazawa H, Tsujikawa T, Fujibayashi Y. Grading of brain glioma with 1-¹¹C-acetate PET: comparison with 18F-FDG PET. Nucl Med Biol. 2008;35(2):171–6.CrossRefPubMed

16.

Yamamoto Y, Nishiyama Y, Kimura N, Kameyama R, Kawai N, Hatakeyama T, et al. ¹¹C-acetate PET in the evaluation of brain glioma: comparison with ¹¹C-methionine and 18F-FDG-PET. Mol Imaging Biol. 2008;10(5):281–7.CrossRefPubMed

17.

Manabe O, Hattori N, Yamaguchi S, Hirata K, Kobayashi K, Terasaka S, et al. Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging. Eur J Nucl Med Mol Imaging. 2015;42(6):896–904.CrossRefPubMed

18.

Waniewski RA, Martin DL. Preferential utilization of acetate by astrocytes is attributable to transport. J Neurosci. 1998;18(14):5225–33.CrossRefPubMed

19.

Dienel GA, Popp D, Drew PD, Ball K, Krisht A, Cruz NF. Preferential labeling of glial and meningial brain tumors with [2-(14)C]acetate. J Nucl Med. 2001;42(8):1243–50.PubMed

20.

Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 2014;159(7):1603–14.CrossRefPubMedPubMedCentral

21.

Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753–64. discussion 264-6CrossRefPubMed

22.

Ito K, Matsuda H, Kubota K. Imaging spectrum and pitfalls of (11)C-Methionine positron emission tomography in a series of patients with intracranial lesions. Korean J Radiol. 2016;17(3):424–34.CrossRefPubMedPubMedCentral

23.

Iversen P, Mouridsen K, Hansen MB, Jensen SB, Sorensen M, Bak LK, et al. Oxidative metabolism of astrocytes is not reduced in hepatic encephalopathy: a PET study with [(11)C]acetate in humans. Front Neurosci. 2014;8:353.CrossRefPubMedPubMedCentral

Titel: The roles of 11C-acetate PET/CT in predicting tumor differentiation and survival in patients with cerebral glioma
verfasst von: Soyoung Kim
Dongwoo Kim
Se Hoon Kim
Mi-ae Park
Jong Hee Chang
Mijin Yun
Publikationsdatum: 06.03.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2018
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-018-3948-9

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease

68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer

Cancer metastasizes to the bone marrow and not to the bone: time for a paradigm shift!

PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer

Extraction, selection and comparison of features for an effective automated computer-aided diagnosis of Parkinson’s disease based on [123I]FP-CIT SPECT images

Imaging αvβ3 integrin expression in skeletal metastases with 99mTc-maraciclatide single-photon emission computed tomography: detection and therapy response assessment